KH CB19 (CAS 1354037-26-5)
See product citations (1)
Available in US only.
QUICK LINKS
KH CB19 is a chemical compound that functions as a potent and selective inhibitor of a specific enzyme. It acts by binding to the active site of the enzyme, preventing its normal function and leading to the inhibition of a cellular process. This inhibition may have a significant impact on the regulation of certain signaling pathways within cells, ultimately affecting cellular growth and proliferation. KH CB19 used to modulate the activity of certain transcription factors, influencing gene expression patterns in a targeted manner. Its mechanism of action involves disrupting specific protein-protein interactions, thereby interfering with the formation of important cellular complexes. This disruption ultimately leads to downstream effects on various cellular processes, making KH CB19 for investigating the molecular mechanisms underlying these processes in experimental applications.
KH CB19 (CAS 1354037-26-5) References
- Kinase inhibition that hinges on halogen bonds. | Grant, SK. and Lunney, EA. 2011. Chem Biol. 18: 3-4. PMID: 21276931
- Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. | Fedorov, O., et al. 2011. Chem Biol. 18: 67-76. PMID: 21276940
- Halogen bonding for rational drug design and new drug discovery. | Lu, Y., et al. 2012. Expert Opin Drug Discov. 7: 375-83. PMID: 22462734
- Regulation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells. | Eisenreich, A., et al. 2013. Oncol Rep. 30: 462-70. PMID: 23604472
- Halogen interactions in protein-ligand complexes: implications of halogen bonding for rational drug design. | Sirimulla, S., et al. 2013. J Chem Inf Model. 53: 2781-91. PMID: 24134121
- Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease. | Jain, P., et al. 2014. Curr Drug Targets. 15: 539-50. PMID: 24568585
- A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. | Shi, Y., et al. 2017. Bioorg Med Chem Lett. 27: 406-412. PMID: 28049589
- Inexpensive High-Throughput Screening of Kinase Inhibitors Using One-Step Enzyme-Coupled Fluorescence Assay for ADP Detection. | Imamura, RM., et al. 2019. SLAS Discov. 24: 284-294. PMID: 30418800
- Regulation of influenza A virus mRNA splicing by CLK1. | Artarini, A., et al. 2019. Antiviral Res. 168: 187-196. PMID: 31176694
- Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945. | Lee, JY., et al. 2019. Biomed Res Int. 2019: 6125068. PMID: 31531359
- [b]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors. | Lechner, C., et al. 2019. Molecules. 24: PMID: 31766108
- LncRNA-dependent nuclear stress bodies promote intron retention through SR protein phosphorylation. | Ninomiya, K., et al. 2020. EMBO J. 39: e102729. PMID: 31782550
- Expression, purification and crystallization of CLK1 kinase - A potential target for antiviral therapy. | Dekel, N., et al. 2020. Protein Expr Purif. 176: 105742. PMID: 32866611
- How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine. | Wurzlbauer, A., et al. 2020. Molecules. 25: PMID: 33339338
- Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases. | Song, M., et al. 2023. Signal Transduct Target Ther. 8: 148. PMID: 37029108
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
KH CB19, 1 mg | sc-362756 | 1 mg | $214.00 | |||
| US: Only available in the US | ||||||
KH CB19, 5 mg | sc-362756A | 5 mg | $612.00 | |||
| US: Only available in the US | ||||||